Close Menu

heart disease

The company signed a non-exclusive license for Zora's ceramide markers and plans to launch a test based on the markers as early as next year.

The firm is developing a test to determine interleukin-6 levels for SARS-CoV-2 patients and a rapid antigen test.

The iQ Group Global is integrating the Wyss Institute's technology with its own organic thin-film biosensor platform for SARS-CoV-2 serology testing. 

The partnership will provide new point-of-care lipid testing devices to remote sites in Latin America, the Caribbean, and Asia-Pacific.

The firm said that it has begun developing its own products using synthetic affinity reagent technology acquired five years ago from the University of Leicester.

Prevencio said that the agreement with Microsoft involves sales of cardiac blood tests to hospitals, life science companies, and contract research organizations.

The Ottawa-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.

The Finnish biotechnology firm also announced plans to raise up to €80 million in the coming year.

The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.

Agilent has partnered with the National University of Singapore and National University Hospital to establish the S$38 million ($27.4 million) research and development facility in Singapore.

Pages